nivolumab,ipilimumab,cabozantinib,sunitinib
bms,pfizer
['nivolumab', 'sunitinib', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'check,mate,9er', 'kcsm,(-skcsm)', 'nivo']
new research from #gu23: longer-term data from checkmate-9er confirm the superiority of first-line nivolumab/cabozantinib versus sunitinib in advanced rcc. #ascodailynews #kcsm
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.